[1]王丽平,刘洋,宋阳.基于药物溶解性和渗透性测定的生物药剂分类系统在兽药制剂研发的应用前景[J].南京农业大学学报,2018,41(2):223-230.[doi:10.7685/jnau.201704041]
 WANG Liping,LIU Yang,SONG Yang.Application prospect of biopharmaceutical classification system based on drug solubility and permeability determination in veterinary drug development[J].Journal of Nanjing Agricultural University,2018,41(2):223-230.[doi:10.7685/jnau.201704041]
点击复制

基于药物溶解性和渗透性测定的生物药剂分类系统在兽药制剂研发的应用前景()
分享到:

《南京农业大学学报》[ISSN:1000-2030/CN:32-1148/S]

卷:
41卷
期数:
2018年2期
页码:
223-230
栏目:
出版日期:
2018-03-27

文章信息/Info

Title:
Application prospect of biopharmaceutical classification system based on drug solubility and permeability determination in veterinary drug development
作者:
王丽平 刘洋 宋阳
南京农业大学动物医学院, 江苏 南京 210095
Author(s):
WANG Liping LIU Yang SONG Yang
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China
关键词:
生物药剂分类系统溶解性渗透性生物等效性豁免兽药
Keywords:
biopharmaceutical classification systemsolubilitypermeabilitybioequivalence waiverveterinary medicine
分类号:
S859.1
DOI:
10.7685/jnau.201704041
摘要:
生物药剂分类系统(BCS)是基于药物溶解性和渗透性测定的药物分类预测系统,目前被FDA、WHO、EMA等权威机构认可并应用于人用药物豁免其体内生物等效性研究。鉴于兽药研发成本及利润等问题,将BCS概念应用于兽药制剂研发领域,势在必行。但是人与动物在解剖、生理学等方面以及在临床使用的药物种类上均存在较大差异,故不能进行直接的种间外推,尚待深入研究以解决局限性和方法问题,才能付诸应用。尽管如此,美国药典专家委员会的特别委员会已经建议将BCS应用于犬,此举无疑具有典范作用和重要的现实意义。
Abstract:
Biopharmaceutical classification system(BCS) is one of the most significant prognostic tools based on drug solubility and permeability. Currently,FDA,WHO and EMA have approved it to be applied as a science-based approach for the waiver of in vivo bioavailability and bioequivalence testing of the drugs used in human medicine. It is imperative to apply BCS to the development of novel veterinary drugs in view of the cost. However,the extrapolation of human criteria to veterinary species is not straightforward due to the difference in anatomy,physiology and types of drugs used in clinic between man and animals. The predictive system must be supported by further studies regarding the limitation and methodology between humans and animals. Nevertheless,the Special Committee of the American Pharmacopoeia Commission has recommended that BCS be applied to dogs,which is undoubtedly a good model and has profound significance.

参考文献/References:

[1] Amidon G L,Lennernas H,Shah V P,et al. A theoretical basis for a biopharmaceutic drug slassification:the correlation of in vitro drug product dissolution and in vivo bioavailability[J]. Pharmaceutical Research,1995,12(3),413-420.
[2] 李新月,叶小强,司俊仁,等. 生物药剂学分类系统及制剂策略[J]. 吉林医药学院学报,2016,37(1):60-63. Li X Y,Ye X Q,Si J R,et al. Biopharmaceutical classification system and formulation strategy[J]. Journal of Jilin Medical College,2016,37(1):60-63(in Chinese with English abstract).
[3] Bonnel R A,Avigan M,Iyasu S. Guidance for industry:waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid products,based on biopharmaceutics classification system[EB/OL].(2007-12-17).http://www.fda.gov/cder/guidance/3618fnl.html.
[4] 高杨,耿立冬. FDA,WHO和EMA关于基于生物药剂学分类系统的生物等效性豁免指导原则的比较[J]. 中国新药杂志,2012,21(24):2861-2869. Gao Y,Geng L D. Comparison of FDA,WHO and EMA guidelines on bioequivalence exemption based on biopharmaceutical classification system[J]. Chinese Journal of New Drugs,2012,21(24):2861-2869(in Chinese with English abstract).
[5] Yu L X,Amidon G L,Polli J E,et al. Biopharmaceutics classification system:the scientific basis for biowaiver extensions[J]. Pharmaceutical Research,2002,19(7):921-925.
[6] 张宁,平其能. 生物药剂分类系统(BCS)及应用进展介绍[J]. 中国新药杂志,2008,17(19):1655-1658. Zhang N,Ping Q N. Biopharmaceutical classification system(BCS)and application progress[J]. Chinese Journal of New Drugs,2008,17(19):1655-1658(in Chinese with English abstract).
[7] 屠锡德. 药剂学[M]. 3版. 北京:人民卫生出版社,2002:1111-1112. Tu X D. Pharmacy[M]. 3rd ed. Beijing:People’s Health Publishing House,2002:1111-1112(in Chinese).
[8] 许鸣镝,王琳,王铁松,等. 生物药剂分类系统差异比较及应用探讨[J]. 中国药学杂志,2016,51(10):777-779. Xu M D,Wang L,Wang T S,et al. Comparison and application of biopharmaceutical classification system[J]. Chinese Pharmaceutical Journal,2016,51(10):777-779(in Chinese with English abstract).
[9] 刘维,杨丽,翟所迪,等,基于药物体内处置的生物药剂学分类系统(BDDCS)简介[J]. 中国新药与临床杂志,2013(4):265-272. Liu W,Yang L,Zhai S D,et al. A brief introduction to biopharmaceutical drug disposition classification system(BDDCS)[J]. Chinese Journal of New Drugs and Clinical Remedies,2013(4):265-272(in Chinese with English abstract).
[10] 胡昌勤,潘瑞雪. 溶出度实验评价/预测固体口服制剂生物等效性的研究进展[J]. 中国新药杂志,2014,23(1):44-51. Hu C Q,Pan R X. Study on the evaluation of bioequivalence of solid oral preparation by dissolution test[J]. Chinese Journal of New Drugs,2014,23(1):44-51(in Chinese with English abstract).
[11] World Health Organization. WHO Technical Report Series No.937. Annex 7:multisource(generic)pharmaceutical products:guidelineson registration requirements to establish interchangeability;Annex 8:proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release,solid oral dosage forms[R]. Geneva:WHO,2006.
[12] EMA. Note for guidance on the investigation of bioavailability and bioequivalence CPMP/WEP/QWP/1401/98 Revl,Appendix Ⅲ[S]. 2006.
[13] 韩静,张丹,刘会臣. 仿制药的生物不等效风险与质量一致性评价[J]. 中国新药杂志,2014,23(24):2897-2901. Han J,Zhang D,Liu H C. Evaluation of risk about bioequivalence unequal and quality consistency of generic drugs[J]. Chinese Journal of New Drugs,2014,23(24):2897-2901(in Chinese with English abstract).
[14] 刘曼,张文萍,张丽娜,等. 基于生物药剂分类系统的口服固体速释制剂生物豁免[J]. 中国新药杂志,2016,25(5):532-542,588. Liu M,Zhang W P,Zhang L N,et al. Biological exemption for oral solid quick release preparation based on biopharmaceutical classification system[J]. Chinese Journal of New Drugs,2016,25(5):532-542,588(in Chinese with English abstract).
[15] 斯陆勤,黄建耿,李高. 生物药剂学分类系统及其应用(下)[J]. 中国药师,2008(2):163-166. Si L Q,Huang J G,Li G. Biopharmaceutical classification system and its application(below)[J]. Chinese Pharmacists,2008(2):163-166(in Chinese).
[16] 高艳春,马苏,康孟佼. 我国兽药行业发展现状及监管方向展望[J]. 中国家禽,2013,35(20):2-5. Gao Y C,Ma S,Kang M J. China’s veterinary drug industry development status and regulatory direction[J]. China Poultry,2013,35(20):2-5(in Chinese with English abstract).
[17] 冯忠武. 兽药行业的现状与发展展望[J]. 中国兽药杂志,2009,43(11):1-7. Feng Z W. Veterinary industry status and development prospects[J]. Chinese Journal of Veterinary Drug,2009,43(11):1-7(in Chinese).
[18] 冯小花,李雄,蔡文杰. 2014年中国兽药行业发展现状及趋势[J]. 今日养猪业,2015(1):46-47. Feng X H,Li X,Cai W J. China’s veterinary drug industry in 2014 the status quo and trends[J]. Pigs Today,2015(1):46-47(in Chinese).
[19] 牛剑钊,林兰,马锐,等. 我国仿制药研究及监管现状[J]. 中国新药杂志,2014,23(1):6-10. Niu J Z,Lin L,Ma R,et cl. China’s generic drug research and supervision of the status quo[J]. Chinese Journal of New Drugs,2014,23(1):6-10(in Chinese).
[20] 解小刚,吴晶. 我国生物仿制药发展现状与策略研究[J]. 中国生物工程杂志,2012,32(3):136-142. Xie X G,Wu J. Study on the current situation and strategy of biomimetic drugs in China[J]. China Biotechnology,2012,32(3):136-142(in Chinese).
[21] Martinez M L,Amidon G,Augsburger L,et al. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. PartⅠ:biopharmaceutics and formulation considerations[J]. Advanced Drug Delivery Reviews,2002,54(6):805-824.
[22] Martinez M N,Papich M G,Riviere J E. Veterinary application of in vitro dissolution data and the Biopharmaceutics Classification System[J]. Pharmacopeial Forum,2004,30(6):2295-2302.
[23] Martinez M L,Amidon G,Augsburger L,et al. Apply the biopharmaceutics classification system to veterinary pharmaceutical products. Part Ⅱ:physiological considerations[J]. Advanced Drug Delivery Reviews,2002,54(6):825-850.
[24] Yamada A,Furuya M,Akimoto T,et al. Evaluation of gastrointestinal transit controlled-beagle dog as a suitable animal model for bioavailability testing of sustained-release acetaminophen dosage form[J]. International Journal of Pharmaceutics,1995,119(1):1-10.
[25] Aoyagi N,Ogata H,Kaniwa N,et al. Bioavailability of griseofulvin from tablets in beagle dogs and correlation with dissolution rate and bioavailability in humans[J]. Journal of Pharmaceutical Sciences,1982,71(10):1169-1172.
[26] Uchida T,Kawata M,Goto S. In vivo evaluation of ethyl cellulose microcapsules containing ampicillin using rabbits,beagle dogs and humans[J]. Journal of Pharmacobio-Dynamics,1986,9(8):631-637.
[27] Kararli T T. Comparison of the gastrointestinal anatomy physiology,and biochemistry of humans and commonly used laboratory animals[J]. Biopharmaceutics and Drug Disposition,1995,16(5):351-380.
[28] Aoyagi N,Ogata H,Kaniwa N,et al. Gastric emptying of tablets and granules in humans,dogs,pigs,and stomach-emptying-controlled rabbits[J]. Journal of Pharmaceutical Sciences,1992,81(12):1170.
[29] Fleisher D,Li C,Zhou Y,et al. Drug,meal and formulation interactions influencing drug absorption after oral administration[J]. Clinical Pharmacokinetics,1999,36(3):233-254.
[30] Papich M G,Martinez M N. Applying biopharmaceutical classification system(BCS)criteria to predict oral absorption of drugs in dogs:challenges and pitfalls[J]. The AAPS Journal,2015,17(4):948-964.
[31] Dressman J B. Comparison of canine and human gastrointestinal physiology[J]. Pharmaceutical Research,1986,3(3):123-131.
[32] Musther H,Olivares-Morales A,Hatley J D,et al. Animal versus human oral drug bioavailability:do they correlate?[J]. European Journal of Pharmaceutical Sciences,2014,57(11):280.
[33] 沃特必姆H,雷纳斯H,阿图松P. 药物生物利用度[M]. 何仲贵,钟大放,张淑秋,译. 北京:化学工业出版社,2006:9. Waterbeemd H,Lennernas H,Artusson P. Drug Bioavailability[M]. He Z G,Zhong D F,Zhang S Q,translation. Beijing:Chemical Industry Press,2006:9(in Chinese).
[34] Haidar S H,Davit B,Chen M L,et al. Bioequivalence approaches for highly variable drugs and drug products[J]. Pharmaceutical Research,2008,25(1):237-241.
[35] For C D E. Guidance for industry-waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system[S]. FDA,2000.
[36] Gray V,Kelly G,Xia M,et al. The science of USP 1 and 2 dissolution:present challenges and future relevance[J]. Pharmaceutical Research,2009,26(6):1289-1302.
[37] Cook J,Addicks W,Wu Y H. Application of the biopharmaceutical classification system in clinical drug development:an industrial view[J]. The AAPS Journal,2008,10(2):306-310.
[38] 衣婷婷. 浅谈增加难溶性兽药溶解度的方法[J]. 山东畜牧兽医,2012(9):82-83. Yi T T. Talk about the method to increase the solubility of insoluble veterinary drugs[J]. Shandong Journal of Animal Science and Veterinary Medicine,2012(9):82-83(in Chinese).
[39] 叶雯,王永禄,李学明. 生物药剂学分类系统在难溶性药物处方设计中的应用[J]. 中国医院药学杂志,2013,33(7):568-570 Ye W,Wang Y L,Li X M. Application of biopharmaceutical classification system in the design of refractory drugs[J]. Chinese Journal of Hospital Pharmacy,2013,33(7):568-570(in Chinese).
[40] 王笃学. 氟苯尼考-PEG6000固体分散的研制及其药效学研究[D]. 长春:吉林大学,2005. Wang D X. Fluorfenicol-PEG6000 solid dispersion of the development and pharmacodynamics research[D]. Changchun:Jilin University,2005(in Chinese with English abstract).
[41] 刘慈. 地克珠利固体分散体制备及质量评价[D]. 保定:河北大学,2010. Liu C. Diclazuril solid dispersion preparation and quality evaluation[D]. Baoding:Hebei University,2010(in Chinese with English abstract).
[42] 姜英. 癸氧喹酯固体分散剂的制备及其抗兔球虫效果的研究[D]. 洛阳:河南科技大学,2013. Jiang Y. Preparation of decanoic acid ester solid dispersant and its effect on anti-rabbit coccidia[D]. Luoyang:Henan University of Science and Technology,2013(in Chinese with English abstract).
[43] 王东军. 头孢噻呋钠在兽医临床中的应用现状及真假鉴别[J]. 北方牧业,2009(7):14. Wang D J. Cefuroxime sodium in veterinary clinical application of the status quo and true and false identification[J]. Northern Animal Husbandry,2009(7):14(in Chinese).
[44] 曹斌. 硫酸头孢喹肟注射液的研制及其初步应用[D]. 扬州:扬州大学,2011. Cao B. Cefquinoxime sulfate injection and its preliminary application[D]. Yangzhou:Yangzhou University,2011(in Chinese with English abstract).
[45] 贾海峰,聂严. 高效液相法测定盐酸沙拉沙星制剂的含量[J]. 中国兽药杂志,2000,9(3):27-28. Jia H F,Nie Y. Determination of the content of salafloxacin hydrochloride by high performance liquid chromatography[J]. Chinese Journal of Veterinary Drug,2000,9(3):27-28(in Chinese with English abstract).
[46] 卢胜明,李英伦. 固体分散技术——一种新型兽药制剂技术[J]. 兽药与饲料添加剂,2003,8(1):43. Lu S M,Li Y L. Solid dispersion technology:a new veterinary drug preparation technology[J]. Veterinary Pharmaceuticals and Feed Additives,2003,8(1):43(in Chinese).

备注/Memo

备注/Memo:
收稿日期:2017-04-27。
基金项目:国家重点研发技术专项(2016YFD0501309)
作者简介:王丽平,教授,主要从事细菌耐药性及生物药剂学在兽医上应用等研究,E-mail:wlp71@163.com。
更新日期/Last Update: 1900-01-01